Claudia Schonefeldt
Dresden, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).
Journal: British journal of haematology
Published: June 08, 2016
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Journal: Annals of hematology
Published: March 16, 2016
Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia.
Journal: Haematologica
Published: September 07, 2014
Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation.
Journal: Blood cancer journal
Published: September 03, 2013
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.
Journal: Haematologica
Published: May 30, 2013
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Journal: Leukemia
Published: January 29, 2013
MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 20, 2012
Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells.
Journal: BMC cancer
Published: August 16, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026